Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

被引:35
作者
Kim, Chang-Gon [1 ]
Sang, Yun-Beom [2 ]
Lee, Ji-Hyun [1 ]
Chon, Hong-Jae [2 ]
机构
[1] Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul 03722, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Med Oncol, Sch Med, Seongnam 13497, South Korea
基金
新加坡国家研究基金会;
关键词
therapeutic cancer vaccine; combination immunotherapy; immune checkpoint inhibitor; tumor microenvironment; T-CELL RESPONSES; PHASE-I TRIAL; DNA VACCINE; DENDRITIC CELLS; TALIMOGENE LAHERPAREPVEC; TUMOR MICROENVIRONMENT; PD-1/PD-L1; BLOCKADE; NEOANTIGEN VACCINE; SYNTHETIC DNA; PD-1;
D O I
10.3390/ijms22158035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapeutic cancer vaccines have become increasingly qualified for use in personalized cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen delivery technologies has assisted in optimizing vaccine design. Therapeutic cancer vaccines aim to establish long-lasting immunological memory against tumor cells, thereby leading to effective tumor regression and minimizing non-specific or adverse events. However, due to several resistance mechanisms, significant challenges remain to be solved in order to achieve these goals. In this review, we describe our current understanding with respect to the use of the antigen repertoire in vaccine platform development. We also summarize various intrinsic and extrinsic resistance mechanisms behind the failure of cancer vaccine development in the past. Finally, we suggest a strategy that combines immune checkpoint inhibitors to enhance the efficacy of cancer vaccines.
引用
收藏
页数:19
相关论文
共 154 条
[1]   Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination [J].
Abdulrahman, Ziena ;
de Miranda, Noel ;
van Esch, Edith M. G. ;
van Steenwijk, Peggy J. de Vos ;
Nijman, Hans W. ;
Welters, Marij J. P. ;
van Poelgeest, Mariette I. E. ;
van der Burg, Sjoerd H. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[2]   Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer [J].
Aggarwal, Charu ;
Cohen, Roger B. ;
Morrow, Matthew P. ;
Kraynyak, Kimberly A. ;
Sylvester, Albert J. ;
Knoblock, Dawson M. ;
Bauml, Joshua M. ;
Weinstein, Gregory S. ;
Lin, Alexander ;
Boyer, Jean ;
Sakata, Lindsay ;
Tan, Sophie ;
Anton, Aubrey ;
Dickerson, Kelsie ;
Mangrolia, Drishty ;
Vang, Russell ;
Dallas, Michael ;
Oyola, Sandra ;
Duff, Susan ;
Esser, Mark ;
Kumar, Rakesh ;
Weiner, David ;
Csiki, Ildiko ;
Bagarazzi, Mark L. .
CLINICAL CANCER RESEARCH, 2019, 25 (01) :110-124
[3]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[4]   PD-1 blockade enhances the vaccination-induced immune response in glioma [J].
Antonios, Joseph P. ;
Soto, Horacio ;
Everson, Richard G. ;
Orpilla, Joey ;
Moughon, Diana ;
Shin, Namjo ;
Sedighim, Shaina ;
Yong, William H. ;
Li, Gang ;
Cloughesy, Timothy F. ;
Liau, Linda M. ;
Prins, Robert M. .
JCI INSIGHT, 2016, 1 (10)
[5]   Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].
Attia, P ;
Phan, GQ ;
Maker, AV ;
Robinson, MR ;
Quezado, MM ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Kammula, US ;
Royal, RE ;
Restifo, NP ;
Haworth, LR ;
Levy, C ;
Mavroukakis, SA ;
Nichol, G ;
Yellin, MJ ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053
[6]   Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal [J].
Baumann, Tobias ;
Dunkel, Andreas ;
Schmid, Christian ;
Schmitt, Sabine ;
Hiltensperger, Michael ;
Lohr, Kerstin ;
Laketa, Vibor ;
Donakonda, Sainitin ;
Ahting, Uwe ;
Lorenz-Depiereux, Bettina ;
Heil, Jan E. ;
Schredelseker, Johann ;
Simeoni, Luca ;
Fecher, Caroline ;
Koerber, Nina ;
Bauer, Tanja ;
Hueser, Norbert ;
Hartmann, Daniel ;
Laschinger, Melanie ;
Eyerich, Kilian ;
Eyerich, Stefanie ;
Anton, Martina ;
Streeter, Matthew ;
Wang, Tina ;
Schraven, Burkhart ;
Spiegel, David ;
Assaad, Farhah ;
Misgeld, Thomas ;
Zischka, Hans ;
Murray, Peter J. ;
Heine, Annkristin ;
Heikenwaelder, Mathias ;
Korn, Thomas ;
Dawid, Corinna ;
Hofmann, Thomas ;
Knolle, Percy A. ;
Hoechst, Bastian .
NATURE IMMUNOLOGY, 2020, 21 (05) :555-+
[7]   Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer [J].
Beer, Tomasz M. ;
Kwon, Eugene D. ;
Drake, Charles G. ;
Fizazi, Karim ;
Logothetis, Christopher ;
Gravis, Gwenaelle ;
Ganju, Vinod ;
Polikoff, Jonathan ;
Saad, Fred ;
Humanski, Piotr ;
Piulats, Josep M. ;
Gonzalez Mella, Pablo ;
Ng, Siobhan S. ;
Jaeger, Dirk ;
Parnis, Francis X. ;
Franke, Fabio A. ;
Puente, Javier ;
Carvajal, Roman ;
Sengelov, Lisa ;
McHenry, M. Brent ;
Varma, Arvind ;
van den Eertwegh, Alfonsus J. ;
Gerritsen, Winald .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :40-+
[8]   Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine [J].
Belnoue, Elodie ;
Mayol, Jean-Francois ;
Carboni, Susanna ;
Besson, Wilma Di Berardino ;
Dupuychaffray, Eloise ;
Nelde, Annika ;
Stevanovic, Stefan ;
Santiago-Bober, Marie-Laure ;
Walker, Paul R. ;
Derouazi, Madiha .
JCI INSIGHT, 2019, 4 (11)
[9]   Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade [J].
Benci, Joseph L. ;
Johnson, Lexus R. ;
Choa, Ruth ;
Xu, Yuanming ;
Qiu, Jingya ;
Zhou, Zilu ;
Xu, Bihui ;
Ye, Darwin ;
Nathanson, Katherine L. ;
June, Carl H. ;
Wherry, E. John ;
Zhang, Nancy R. ;
Ishwaran, Hemant ;
Hellmann, Matthew D. ;
Wolchok, Jedd D. ;
Kambayashi, Taku ;
Minn, Andy J. .
CELL, 2019, 178 (04) :933-+
[10]   The emerging clinical relevance of genomics in cancer medicine [J].
Berger, Michael F. ;
Mardis, Elaine R. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (06) :353-365